Treatment for experimental autoimmune neuritis with clodronate (Bonefos)

Area of Science:

• Neuroimmunology
• Pharmacology

Background:

• Experimental autoimmune neuritis (EAN) models human Gullain-Barre syndrome (GBS), a peripheral nerve autoimmune disorder.
• Macrophages are key inflammatory cells in EAN/GBS and can be targeted by bisphosphonates.

Purpose of the Study:

• To investigate the therapeutic effect of the bisphosphonate clodronate on the EAN model.
• To assess clodronate's impact on clinical signs and inflammatory markers in EAN.

Main Methods:

• EAN induced in rats via immunization with bovine peripheral myelin.
• Rats treated with clodronate (20 mg/kg daily or 40 mg/kg every 2 days) post-clinical onset.
• Clinical scores, Rotarod performance, body weight, and sciatic nerve MMP-9 expression were evaluated.

Main Results:

• Clodronate treatment significantly reduced EAN severity by 75% (p < 0.01).
• Motor performance and body weight improvements corroborated clinical findings.
• Reduced MMP-9 expression in sciatic nerves indicated decreased inflammatory macrophages.

Conclusions:

• Clodronate effectively mitigates disease severity in the EAN model.
• Inhibition of inflammatory macrophages is a key mechanism of clodronate's action.
• Bisphosphonates, like clodronate, warrant consideration for human GBS treatment.